KRYS

Krystal Biotech, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$305.68

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30

Non-compliant assets / Total market cap %12.7 / %30

Non-compliant revenue / Total income %6.3 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Website

Analysis (Turkish): KRYS Hissesi Caiz mi, Helal mi? Krystal Biotech, Inc. Katılım Analizi